Shares of Array BioPharma, Inc. (ARRY) reached a new 52-week high of $7.58 on Friday's intraday trading, after the company reported that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), currently in Phase 3 development for the treatment of melanoma.
The agreement is conditional on Novartis closing some transactions with GlaxoSmithKline PLC that it announced on April 22, 2014, which are expected to close in the first half of 2015
Upon satisfaction of all conditions and closing of the deal, ARRY will acquire global rights to encorafenib. Other than a de minimis payment due to Novartis from ARRY, there are no milestone payments or royalties payable under this agreement by either party.
Encorafenib is a potent and highly selective small molecule BRAF inhibitor that targets a key enzyme in this pathway and has shown clinical activity in a Phase 1 study in advanced tumors including melanoma and metastatic colorectal cancer.
ARRY is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
More about Array BioPharma, Inc. (ARRY) at www.arraybiopharma.com.
**
The price of Nevro Corp. (NVRO) stock soared more than 18% on Friday, following the announcement that it has received a letter from the U.S. Food and Drug Administration (FDA) informing the company of the approvability of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system.
According to the approvable letter, approval of the PMA is subject to satisfaction of regulatory inspections and audits of manufacturing facilities, methods and controls for Senza to ensure compliance with the FDA's Quality System Regulation, as well as finalization of the product's labeling with the FDA.
NVRO said that it is working to satisfy the conditions of approval and anticipates initial commercial availability in the U.S. by mid-2015.
The Senza system is the only SCS system that delivers NVRO's proprietary HF10 therapy, an SCS therapy that provides electrical pulses to the spinal cord to alleviate pain. The electrical pulses are delivered by small electrodes on leads that are placed near the spinal cord and are connected to a compact, battery-powered generator implanted under the skin.
NVRO is a medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain.
More about Nevro Corp. (NVRO) at www.nevro.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Pomona, CA ( www.pomona.crwe-pr.com ) into the CRWE Network.
Pomona is the fifth largest city in Los Angeles County, California. It is located in the Pomona Valley, between the Inland Empire and the San Gabriel Valley, about thirty minutes west of the City of Los Angeles.
The City of Pomona had an estimated population in 2013 (U.S. Census Bureau) of 151,348, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
The agreement is conditional on Novartis closing some transactions with GlaxoSmithKline PLC that it announced on April 22, 2014, which are expected to close in the first half of 2015
Upon satisfaction of all conditions and closing of the deal, ARRY will acquire global rights to encorafenib. Other than a de minimis payment due to Novartis from ARRY, there are no milestone payments or royalties payable under this agreement by either party.
Encorafenib is a potent and highly selective small molecule BRAF inhibitor that targets a key enzyme in this pathway and has shown clinical activity in a Phase 1 study in advanced tumors including melanoma and metastatic colorectal cancer.
ARRY is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
More about Array BioPharma, Inc. (ARRY) at www.arraybiopharma.com.
**
The price of Nevro Corp. (NVRO) stock soared more than 18% on Friday, following the announcement that it has received a letter from the U.S. Food and Drug Administration (FDA) informing the company of the approvability of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system.
According to the approvable letter, approval of the PMA is subject to satisfaction of regulatory inspections and audits of manufacturing facilities, methods and controls for Senza to ensure compliance with the FDA's Quality System Regulation, as well as finalization of the product's labeling with the FDA.
NVRO said that it is working to satisfy the conditions of approval and anticipates initial commercial availability in the U.S. by mid-2015.
The Senza system is the only SCS system that delivers NVRO's proprietary HF10 therapy, an SCS therapy that provides electrical pulses to the spinal cord to alleviate pain. The electrical pulses are delivered by small electrodes on leads that are placed near the spinal cord and are connected to a compact, battery-powered generator implanted under the skin.
NVRO is a medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain.
More about Nevro Corp. (NVRO) at www.nevro.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Pomona, CA ( www.pomona.crwe-pr.com ) into the CRWE Network.
Pomona is the fifth largest city in Los Angeles County, California. It is located in the Pomona Valley, between the Inland Empire and the San Gabriel Valley, about thirty minutes west of the City of Los Angeles.
The City of Pomona had an estimated population in 2013 (U.S. Census Bureau) of 151,348, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
